P
Last Price
52 Week Range
- - -
Next Earnings Date
-
Next Earnings Date
-
Last Price
Market Cap | HK$26.99B |
EV | HK$26.72B |
Shares Outstanding | 391.09M |
Beta | - |
Industry | - |
Analyst Rating | BUY |
Analyst Target Price | |
Number of Analysts | 1 |
P/E 2020E | - |
P/Revenue 2020E | - |
Revenue | |
EPS | |
Operating Cash Flow | |
Free Cash Flow |
Revenue | |
EPS | |
Operating Cash Flow | |
Free Cash Flow |
Gross Margin 2020E | - |
Net Profit Margin 2020E | - |
ROE 2020E | - |
ROCE 2019 | - |
DPS 2020E | - |
Payout Ratio 2020E | - |
Div. Yield 2020E | - |
DPS Last 3Y CAGR |
Price
%
1M
3M
6M
1Y
3Y
5Y
P
PegBio Co., Ltd.
2565
Sector
Industry
CEO
Xu, Min
Employees
58
Website
www.pegbio.comIPO Date
Headquarters
Room 606, Building 1, Haozhang Tower, Gongshu District, Hangzhou, Zhejiang Province, 215123, China
Based on current 2565 analyst forecasts and market assumptions, the consensus price target for PegBio (2565) is HK$101.80 for 2027. Price targets reflect forward-looking estimates based on information available at the time and are inherently subject to change as underlying assumptions, company fundamentals, or market conditions evolve. Last updated:
The current PegBio (2565) market capitalization is approximately HK$26.99B, based on its latest share price and shares outstanding. Market capitalization represents the total market value of a company's equity and is calculated by multiplying the current stock price by the number of shares outstanding. As a result, PegBio's market cap fluctuates with changes in its share price and share count. Last updated: December 31, 2025 at 11:55 PM Eastern Time
In the most recently reported fiscal year, PegBio (2565) generated net income of HK$-0.23B. Net income may be positive or negative and can fluctuate materially from year to year due to changes in operating performance, non-recurring or one-time items, accounting treatments, capital structure, and broader macroeconomic conditions.
PegBio (2565) does not currently pay a dividend. Over the last twelve months (LTM), the company paid HK$0.00 per share in dividends, and no dividend payments are currently expected over the next twelve months (NTM). Companies that do not pay dividends typically prioritize reinvesting cash into growth initiatives, capital expenditures, debt reduction, or strategic investments, though dividend policy may change in the future.
Analyst assessments of whether PegBio (2565) consensus price target is overvalued or undervalued are generally expressed relative to consensus valuation frameworks and price targets, rather than as an absolute judgment.Consensus price target: HK$101.80 An implied return above current levels indicates that, on average, analysts view the stock as trading below their estimated fair value. Conversely, an implied return below current levels suggests the stock may be fully valued or priced above consensus expectations. This content is for informational purposes only and does not constitute investment advice.
Based on the latest available analyst coverage, PegBio (2565) currently carries a Buy consensus rating. Analyst views are forward-looking estimates and should not be considered investment advice.
Like other publicly traded stocks, PegBio (2565) shares are bought and sold on stock exchanges such as SEHK and other supported markets, depending on the listing. The most common way to buy shares is through an online brokerage account. To get started, you typically need to: Open an account with a licensed stock brokerComplete the broker's verification processFund your accountPlace a buy order for PegBio (2565) shares Trading involves risk, and investors should consider their financial objectives and risk tolerance before investing.
At the top right of this page, you'll see a star icon labeled Add to watchlist. Click it to add 2565 to your watchlist.
PegBio trades under the ticker symbol 2565 on the SEHK stock exchange. The ticker 2565 is used to identify the company's common stock across trading platforms, market data providers, and regulatory filings.
As of the most recently reported period, PegBio (2565) employs approximately 58 people worldwide. Reported employee figures may fluctuate over time due to hiring activity, restructuring, automation initiatives, or changes in business strategy. Headcount data is typically disclosed in company filings and reflects full-time employees unless otherwise stated. Last updated: December 31, 2025 at 11:55 PM Eastern Time
Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2026, S&P Global Market Intelligence. All rights reserved.
View Data ProvidersNEWSLETTER
Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2026, S&P Global Market Intelligence. All rights reserved.
View Data ProvidersGainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.